Top 5 Biotech Venture Capital Deals, H1 2010

The first half of 2010 has drawn to a close, so it's time to look back on the biggest biotech venture capital deals so far this year. At the halfway point the leader is Archimedes Pharma, and England-based developer that has raised $100 million to support the planned roll-out of PecFent, a fentanyl nasal spray designed to treat breakthrough cancer pain. Overall, the biotech industry has raised $2.1 billion in 238 deals through the end of June 2010, according to the National Venture Capital Association.

Archimedes Pharma $100M
Tesaro  $60M
Achaogen  $56M
NGM Biopharmaceuticals $51M
Neurotherapeutics Pharma

$43M

Read more on

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.